Skip to main content

Table 2 Tumor architectural growth patterns by clinicopathologic characteristics

From: Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma

 

Overall

Micropapillary

Papillary

Pseudoglandular

Solid

 

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

N

79

30

49

 

19

60

 

19

60

 

23

56

 

Age at diagnosis, mean (SD)

61.4 (11.1)

61.3

(9.1)

61.4 (12.2)

0.97

62.2 (7.4)

61.1 (12.1)

0.64

60.9 (11.3)

61.5 (11.1)

0.84

63.1 (13.0)

60.7 (10.3)

0.38

Stage, n (%)

 I,II

8 (10)

8 (27)

0 (0)

0.0002

2 (11)

6 (10)

0.33

2 (11)

6 (10)

0.33

2 (9)

6 (11)

0.32

 III,IV

71 (90)

22 (73)

49 (100)

 

17 (89)

54 (90)

 

17 (89)

54 (90)

 

21 (91)

50 (89)

 

Debulking status, n (%)

 Suboptimal

18 (24)

4 (14)

14 (30)

0.07

4 (21)

14 (25)

0.24

3 (17)

15 (26)

0.19

7 (32)

11 (20)

0.29

 Optimal

58 (76)

25 (86)

33 (70)

 

15 (79)

43 (75)

 

15 (83)

43 (74)

 

15 (68)

43 (80)

 

Lymphovascular Invasion, n (%)

 Yes

62 (79)

15 (50)

47 (96)

<.0001

16 (84.2)

46 (77)

0.21

14 (74)

48 (80)

0.20

17 (74)

45 (80)

0.53

 No

17 (21)

15 (50)

2 (4)

 

3 (16)

14 (23)

 

5 (26)

12 (20)

 

6 (26)

11 (20)

 

Cystic Component, n (%)

 Yes

54 (69)

20 (67)

34 (7)

0.70

9 (50)

45 (75)

0.04

14 (78)

40 (67)

0.16

16 (7)

38 (68)

0.68

 No

24 (30)

10 (33)

14 (29)

 

9 (50)

15 (25)

 

4 (22)

20 (33)

 

6 (27)

18 (32)

 

STIC, n (%)

 Yes

20 (25)

6 (23)

14 (31)

0.47

2 (12)

18 (33)

0.06

1 (7)

19 (34)

0.03

9 (43)

11 (22)

0.08

 No

51 (65)

20 (77)

31 (69)

 

15 (88)

36 (67)

 

14 (93)

37 (66)

 

12 (57)

39 (78)

 

TIL, n (%)

 Yes

32 (41)

13 (43)

19 (40)

0.74

10 (56)

22 (37)

0.15

6 (33)

26 (43)

0.45

7 (32)

25 (45)

0.30

 No

46 (58)

17 (57)

29 (60)

 

8 (44)

38 (63)

 

12 (67)

34 (57)

 

15 (68)

31 (55)

 

Response to therapy

 Sensitive

59 (76)

24 (83)

35 (71)

0.26

15 (79)

44 (75)

0.70

15 (79)

44 (75)

0.7

18 (78)

41 (75)

0.73

 Resistant

19 (24)

5 (17)

14 (29)

 

4 (21)

15 (25)

 

4 (21)

15 (25)

 

5 (22)

14 (25)

 

Vital Status, n (%)

 Alive

24 (30)

15 (50)

9 (18)

0.003

9 (47)

15 (25)

0.06

5 (26)

19 (32)

0.66

6 (26)

18 (32)

0.59

 Dead

55 (70)

15 (50)

40 (82)

 

10 (53)

45 (75)

 

14 (74)

41 (68)

 

17 (74)

38 (68)

 
  1. STIC serous tubal intraepithelial carcinoma, TIL tumor-infiltrating lymphocytes, SD standard deviation